BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol 2021;35:e22708. [PMID: 33491255 DOI: 10.1002/jbt.22708] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
2 Mortezaee K, Majidpoor J, Najafi S. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life Sciences 2022;310:121083. [DOI: 10.1016/j.lfs.2022.121083] [Reference Citation Analysis]
3 Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 2022;156:113906. [DOI: 10.1016/j.biopha.2022.113906] [Reference Citation Analysis]
4 Mortezaee K, Majidpoor J. Extracellular vesicle-based checkpoint regulation and immune state in cancer. Med Oncol 2022;39:225. [PMID: 36175741 DOI: 10.1007/s12032-022-01837-2] [Reference Citation Analysis]
5 Liu T, Cheng S, Xu Q, Wang Z. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Kaunas) 2022;58:1298. [PMID: 36143975 DOI: 10.3390/medicina58091298] [Reference Citation Analysis]
6 Xia J, Zhang S, Zhang R, Wang A, Zhu Y, Dong M, Ma S, Hong C, Liu S, Wang D, Wang J. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01623-2] [Reference Citation Analysis]
7 Mortezaee K, Majidpoor J, Kharazinejad E. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Med Oncol 2022;39:193. [PMID: 36071302 DOI: 10.1007/s12032-022-01801-0] [Reference Citation Analysis]
8 Tian X, Zheng J, Mou W, Lu G, Chen S, Du J, Zheng Y, Chen S, Shen B, Li J, Wang N. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma. Front Pharmacol 2022;13:939542. [DOI: 10.3389/fphar.2022.939542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
10 Xie F, Huang X, He C, Wang R, Li S. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer. Front Mol Biosci 2022;9:876607. [PMID: 35755810 DOI: 10.3389/fmolb.2022.876607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sun X, Yang N, Zhou X, Dai H, Li Q, Feng A, Xu G, Liu Y, Xu L, Zhang Z, Yang Z, Li X. CILP, a Putative Gene Associated With Immune Infiltration in Breast Cancer Brain Metastases. Front Genet 2022;13:862264. [PMID: 35711946 DOI: 10.3389/fgene.2022.862264] [Reference Citation Analysis]
12 Mortezaee K, Majidpoor J. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy. Cell Oncol (Dordr) 2022. [PMID: 35587857 DOI: 10.1007/s13402-022-00667-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hsu FT, Tsai CL, Chiang IT, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med 2022. [PMID: 35174623 DOI: 10.1111/jcmm.17220] [Reference Citation Analysis]
17 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
18 Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci 2021;286:120057. [PMID: 34662552 DOI: 10.1016/j.lfs.2021.120057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
19 Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2021. [PMID: 34773527 DOI: 10.1007/s10147-021-02074-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
20 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
21 Wharton KA Jr, Wood D, Manesse M, Maclean KH, Leiss F, Zuraw A. Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation. Front Mol Biosci 2021;8:672531. [PMID: 34386519 DOI: 10.3389/fmolb.2021.672531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
22 Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int Immunopharmacol 2021;98:107836. [PMID: 34218217 DOI: 10.1016/j.intimp.2021.107836] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
23 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
24 Melendez-Zajgla J, Maldonado V. The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2021;22:6374. [PMID: 34203589 DOI: 10.3390/ijms22126374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
25 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
26 Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology 2021;226:108707. [DOI: 10.1016/j.clim.2021.108707] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 42.0] [Reference Citation Analysis]
27 Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncology 2021;17:1943-61. [DOI: 10.2217/fon-2020-1103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
28 Barman S, Fatima I, Singh AB, Dhawan P. Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. Int J Mol Sci 2021;22:4765. [PMID: 33946266 DOI: 10.3390/ijms22094765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]